[Experience with surfactant used in the treatment of patients with lingering pneumonia].
Two groups of patients were followed up. Group 1 consisted of 70 patients receiving inhaled Surfactant-BL through a bronchoalveolar nebulizer. Group 2 (control) included 40 patients with lingering pneumonia untreated with the surfactant. Physical studies and determination of the intensity of cough were made in all the patients on admission and 2 weeks later. In this study, there were no adverse reactions caused by surfactant in patients with lingering pneumonia. Following 14 days of therapy, there was a reduction in the intensity of cough in the study group patients as compared to the controls. Concurrently, the values of external respiration function significantly improved as compared to the baseline ones and the controls. A higher clinical efficiency of treatment was noted in patients with lingering pneumonia treated with surfactant than in those untreated with this agent.
Velikaia
O V
OV
Provorotov
V M
VM
Machikina
E I
EI
D000280:Administration, Inhalation; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D003371:Cough / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers; D011014:Pneumonia / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000627:therapeutic use*; D013902:Radiography, Thoracic; D012720:Severity of Illness Index; D016896:Treatment Outcome
D011663:Pulmonary Surfactants